Profound Medical PROF 深 滬
已收盤 11-06 16:00:00 美东时间
7.21
+0.330
+4.80%
華盛通- 最 高7.22
- 今 開6.46
- 成交量 32.24万股
- 最 低 6.155
- 昨 收 6.88
- 總市值 2.63亿
- 52周最高 8.95
- 市盈率 靜 --
- 換手率 0.88%
- 52周最低 4.80
- 委 比 22.78%
- 總股本 3654.03万
- 歷史最高 28.97
- 量 比 0.99
- 振 幅 15.48%
- 歷史最低 3.10
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Profound Medical Q3 EPS $(0.21) Misses $(0.19) Estimate, Sales $9.830M Miss $9.867M Estimate
Profound Medical (NASDAQ:PROF) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 19.23 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $9.830 mill...
11-06 05:14
Profound Medical Strikes Supply, Distribution Deal With iMRI Division Of Cook Medical To Expand Sales Of TULSA-PRO System In U.S.
Profound Medical Corp. (NASDAQ:PROF, (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI ("iMRI") procedures, today announced that it has entered into a supply and distribution agreement with the iMRI...
10-30 20:02
Profound Medical and Cook Medical’s iMRI Division Partner to Expand U.S. TULSA-PRO® Sales Channels and Drive Recurring Revenue Growth
Profound Medical Corp.与Cook Medical达成分销协议，将TULSA-PRO系统纳入Cook的iMRI Suite，扩大其在美国的销售。该协议使Cook能够向医院提供完整的前列腺治疗解决方案，同时Profound保留耗材和服务收入。合作旨在增加系统安装量，提升医生和患者对TULSA Procedure的可及性，并与Siemens Healthineers的现有合作相辅相成，共同推动MRI引导下前列腺消融的普及。
10-30 12:00
Profound Medical Enlists Montel Williams to Amplify Prostate Care Advocacy
Profound Medical ( ($TSE:PRN) ) just unveiled an update. Profound Medical is ex...
10-23 04:41
Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar
Profound Medical Corp. announced that Montel Williams, an Emmy Award-winning TV host and health advocate, will join the next "Let’s Huddle" webinar on November 5, 2026. The webinar aims to discuss health advocacy, resilience, and informed healthcare decisions, particularly for prostate care. Williams, a U.S. Navy veteran and founder of the Montel Williams MS Foundation, will share his insights. Profound Medical emphasizes patient education and in...
10-22 20:15
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound Medical Corp. and Telix Pharmaceuticals have entered a co-education agreement to integrate Telix’s PSMA-PET imaging technologies with Profound’s MRI-guided TULSA-PRO platform for improved prostate cancer care. The collaboration aims to enhance physician education, optimize patient selection, and expand access to advanced treatment options. Profound plans to incorporate PSMA-PET data into future software updates, potentially improving tre...
10-09 11:45
Profound Medical Sees Q3 Sales $9.800M-$10.000M vs $6.934M Est
Profound Medical (NASDAQ:PROF) sees Q3 sales of $9.800 million-$10.000 million vs $6.934 million analyst estimate.
10-08 05:28
Profound Medical Forecasts Record Q3 Revenue, Far Exceeds Street Estimates
Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical ex...
10-08 05:02
Profound Medical expects Q3 revenue could top estimates by 47%
Profound Medical (PROF) announced on Wednesday that it expects Q3 revenue of $9.8M-$10.0M, up 85%-89% YoY and 292%-300% QoQ. The preliminary revenue range is about 45%-47% above the $6.78M Bloomberg c...
10-08 04:28
Profound Medical Reports Q3 Preliminary Revenue Range $9.8M - $10M, Up ~85% To 89% YoY
Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced preliminary unaudited revenues for the third quarter ended September 30, 2026. Preliminary...
10-08 04:16
